All Title Author
Keywords Abstract

PLOS Medicine  2012 

HIV Treatment as Prevention: Principles of Good HIV Epidemiology Modelling for Public Health Decision-Making in All Modes of Prevention and Evaluation

DOI: 10.1371/journal.pmed.1001239

Full-Text   Cite this paper   Add to My Lib

Abstract:

Public health responses to HIV epidemics have long relied on epidemiological modelling analyses to help prospectively project and retrospectively estimate the impact, cost-effectiveness, affordability, and investment returns of interventions, and to help plan the design of evaluations. But translating model output into policy decisions and implementation on the ground is challenged by the differences in background and expectations of modellers and decision-makers. As part of the PLoS Medicine Collection “Investigating the Impact of Treatment on New HIV Infections”—which focuses on the contribution of modelling to current issues in HIV prevention—we present here principles of “best practice” for the construction, reporting, and interpretation of HIV epidemiological models for public health decision-making on all aspects of HIV. Aimed at both those who conduct modelling research and those who use modelling results, we hope that the principles described here will become a shared resource that facilitates constructive discussions about the policy implications that emerge from HIV epidemiology modelling results, and that promotes joint understanding between modellers and decision-makers about when modelling is useful as a tool in quantifying HIV epidemiological outcomes and improving prevention programming.

References

[1]  Riley S, Fraser C, Donnelly CA, Ghani AC, Abu-Raddad LJ, et al. (2003) Transmission dynamics of the etiological agent of SARS in Hong Kong: impact of public health interventions. Science 300: 1961–1966.
[2]  Fraser C, Donnelly CA, Cauchemez S, Hanage WP, Van Kerkhove MD, et al. (2009) Pandemic potential of a strain of influenza A (H1N1): early findings. Science 324: 1557–1561.
[3]  Grassly NC, Fraser C, Wenger J, Deshpande JM, Sutter RW, et al. (2006) New strategies for the elimination of polio from India. Science 314: 1150–1153.
[4]  Griffin JT, Hollingsworth TD, Okell LC, Churcher TS, White M, et al. (2010) Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies. PLoS Med 7: e1000324. doi:10.1371/journal.pmed.1000324.
[5]  Salomon JA, Hogan DR, Stover J, Stanecki KA, Walker N, et al. (2005) Integrating HIV prevention and treatment: from slogans to impact. PLoS Med 2: e16. doi:10.1371/journal.pmed.0020016.
[6]  Schwartlander B, Stover J, Hallett T, Atun R, Avila C, et al. (2011) Towards an improved investment approach for an effective response to HIV/AIDS. Lancet 377: 2031–2041.
[7]  Eaton JW, Johnson LF, Salomon JA, B?rnighausen T, Bendavid E, et al. (2012) HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med 9: e1001245. doi:10.1371/journal.pmed.1001245.
[8]  Garnett GP, Cousens S, Hallett TB, Steketee R, Walker N (2011) Mathematical models in the evaluation of health programmes. Lancet 378: 515–525.
[9]  Grassly NC, Fraser C (2008) Mathematical models of infectious disease transmission. Nat Rev Microbiol 6: 477–487.
[10]  Wilson DP, Garnett GP (2011) Introductions to recent developments in HIV epidemic modelling. Curr Opin HIV AIDS 6: 91–93.
[11]  Keeling MJ, Rohani P (2007) Modeling infectious diseases in humans and animals. Princeton: Princeton University Press.
[12]  Vynnycky E, White R (2010) An Introduction to Infectious Disease Modelling. Oxford: Oxford University Press.
[13]  Hankins CA, Glasser JW, Chen RT (2011) Modeling the impact of RV144-like vaccines on HIV transmission Vaccine 29: 6069–6071.
[14]  McLean AR, Blower SM (1993) Imperfect vaccines and herd immunity to HIV. Proc Biol Sci 253: 9–13.
[15]  Anderson R, Hanson M (2005) Potential public health impact of imperfect HIV type 1 vaccines. J Infect Dis 191: S85–S96.
[16]  Smith RJ, Bodine EN, Wilson DP, Blower SM (2005) Evaluating the potential impact of vaginal microbicides to reduce the risk of acquiring HIV in female sex workers. AIDS 19: 413–421.
[17]  Foss AM, Vickerman PT, Heise L, Watts CH (2003) Shifts in condom use following microbicide introduction: should we be concerned? AIDS 17: 1227–1237.
[18]  Desai K, Sansom SL, Ackers ML, Stewart SR, Hall HI, et al. (2008) Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS 22: 1829–1839.
[19]  UNAIDS/WHO/SACEMA Expert Group on Modelling the Impact and Cost of Male Circumcision for HIV Prevention (2009) Male circumcision for HIV prevention in high HIV prevalence settings: what can mathematical modelling contribute to informed decision making? PLoS Med 6: e1000109. doi:10.1371/journal.pmed.1000109.
[20]  Delva W, Eaton JW, Meng F, Fraser C, White RG, et al. (2012) HIV treatment as prevention: optimising the impact of expanded HIV treatment programmes. PLoS Med 9: e1001258. doi:10.1371/journal.pmed.1001258.
[21]  Hallett TB, Garnett GP, Mupanberiyi Z, Gregson S (2008) Measuring effectiveness in community randomized trials of HIV prevention. Int J Epidemiol 37: 77–87.
[22]  Althaus CL, Turner KM, Schmid BV, Heijne JC, Kretzschmar M, et al. (2012) Transmission of Chlamydia trachomatis through sexual partnerships: a comparison between three individual-based models and empirical data. J R Soc Interface 9: 136–146.
[23]  Models of Infectious Diseases Agent Study (2011) MIDAS model profiles. Available: https://www.epimodels.org/midas/modelPro?filesFull.do. Accessed 1 December 2011.
[24]  Baggaley RF, Ferguson NM, Garnett GP (2005) The epidemiological impact of antiretroviral use predicted by mathematical models: a review. Emerg Themes Epidemiol 2: 9.
[25]  Johnson LF, Hallett TB, Rehle TM, Dorrington RE (2012) The effect of changes in condom usage and antiretroviral treatment coverage on human immunodeficiency virus incidence in South Africa: a model-based analysis. J R Soc Interface. E-pub ahead of print. doi:10.1098/rsif.2011.0826.
[26]  Prestage GP, McCann P, Gray R, Hoare A, Down I, et al. (2011) The development of Australia's national syphilis action plan is based in interdisciplinary research findings. Int J Interdiscip Soc Sci 5: 239–261.
[27]  Gray RT, Heymer KJ, Hoare A, Kwon JA, Thein HH, et al. (2009) What impact might the economic crisis have on HIV epidemics in Southeast Asia? Curr HIV Res 7: 656–665.
[28]  Blower SM, Dowlatabadi H (1994) Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV model, as an example. Int Stat Rev 2: 229–243.
[29]  Wilson DP, Coplan PM, Wainberg MA, Blower SM (2008) The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics. Proc Natl Acad Sci U S A 105: 9835–9840.
[30]  Smith RJ, Okano JT, Kahn JS, Bodine EN, Blower S (2010) Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco. Science 327: 697–701.
[31]  Alkema L, Raftery AE, Clark SJ (2007) Probabilistic projections of HIV prevalence using Bayesian melding. Ann Appl Stat 1: 229–248.
[32]  Johnson L, Dorrington R, Bradshaw D, Pillay-Van Wyk V, Rehle T (2009) Sexual behaviour patterns in South Africa and their association with the spread of HIV: insights from a mathematical model. Demogr Res 21: 289–340. doi:10.4054/DemRes.2009.21.11.
[33]  Box G, Draper NR (1987) Empirical model-building and response surfaces. Oxford: John Wiley & Sons.
[34]  Abu-Raddad LJ, Schiffer JT, Ashley R, Mumtaz G, Alsallaq RA, et al. (2010) HSV-2 serology can be predictive of HIV epidemic potential and hidden sexual risk behavior in the Middle East and North Africa. Epidemics 2: 173–182.
[35]  Anderson RM, May RM (1991) Infectious disease of humans: dynamics and control. Oxford: Oxford University Press.
[36]  Abu-Raddad LJ, Patnaik P, Kublin JG (2006) Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa. Science 314: 1603–1606.
[37]  Marino S, Hogue IB, Ray CJ, Kirschner DE (2008) A methodology for performing global uncertainty and sensitivity analysis in systems biology. J Theor Biol 254: 178–196.
[38]  Abu-Raddad L, Longini IM (2008) No HIV stage is dominant in driving the HIV epidemic in sub-Saharan Africa. AIDS 22: 1055–1061.
[39]  Wilson DP, Garnett GP (2011) Introduction to recent developments in HIV epidemic modeling. Curr Opin HIV AIDS 6: 91–93.
[40]  The HIV Modelling Consortium Treatment as Prevention Editorial Writing Group (2012) HIV treatment as prevention: models, data, and questions—Towards evidence-based decision-making. PLoS Med 9: e1001259. doi:10.1371/journal.pmed.1001259.
[41]  Long EF, Brandeau ML, Owens DK (2010) The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med 153: 778–789.
[42]  Anderson JS, Wilson D, Templeton DJ, Grulich A, Carter R, et al. (2009) Cost-effectiveness of adult circumcision for HIV prevention in men who have sex with men in a resource-rich setting. J Infect Dis 200: 1803–1812.
[43]  Vickerman P, Kumaranayake L, Balakireva O, Guinness L, Artyukh O, et al. (2006) The cost-effectiveness of expanding harm reduction activities for injecting drug users in Odessa, Ukraine. Sex Transm Dis 33: S89–S102.
[44]  Alistar SS, Owens DK, Brandeau ML (2011) Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine. PLoS Med 8: e1000423. doi:10.1371/journal.pmed.1000423.
[45]  Drummond MF, Jefferson TO (1996) Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 313: 275–283.
[46]  Kaiser Family Foundation (2011) International AIDS assistance from donor governments: commitments & disbursements, 2002–2010. Available: http://facts.kff.org/chart.aspx?ch=946. Accessed 25 November 2011.
[47]  Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493–505.
[48]  Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG (2009) Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373: 48–57.
[49]  Wagner BG, Kahn JS, Blower S (2010) Should we try to eliminate HIV epidemics by using a ‘test and treat’ strategy? AIDS 24: 775–776.
[50]  Hallett TB, White PJ, Garnett GP (2007) Appropriate evaluation of HIV prevention interventions: from experiment to full-scale implementation. Sex Transm Infect 83: i55–i60.

Full-Text

comments powered by Disqus